Roivant Sciences Ltd Ordinary Shares ROIV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ROIV is a good fit for your portfolio.
News
-
Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
-
Pfizer shares downgraded as patent expirations loom
-
Roivant Sciences shares drop as lupus treatment misses trial goal
-
Trending: Roche to Buy Telavant From Roivant and Pfizer
-
Roivant, Pfizer shares rise as Roche agrees to buy immunology company for $7.1 billion
-
Roche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Billion — Update
-
Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Billion Deal
-
Roivant stock rallies on report of pending drug sale: WSJ
Trading Information
- Previous Close Price
- $10.88
- Day Range
- $10.88–11.11
- 52-Week Range
- $8.06–13.24
- Bid/Ask
- $10.80 / $11.15
- Market Cap
- $8.89 Bil
- Volume/Avg
- 3.1 Mil / 7.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 70.96
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 904
- Website
- —
Comparables
Valuation
|
Metric
|
ROIV
|
IMVT
|
FDMT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.44 | 5.93 | 3.29 |
Price/Sales | 70.96 | — | 44.43 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ROIV
|
IMVT
|
FDMT
|
|---|---|---|---|
Quick Ratio | 27.50 | 21.56 | 15.21 |
Current Ratio | 27.79 | 22.14 | 15.65 |
Interest Coverage | 116.77 | — | — |
Quick Ratio
ROIV
IMVT
FDMT
Profitability
|
Metric
|
ROIV
|
IMVT
|
FDMT
|
|---|---|---|---|
Return on Assets (Normalized) | −24.87% | −43.33% | −25.94% |
Return on Equity (Normalized) | −39.81% | −47.83% | −28.64% |
Return on Invested Capital (Normalized) | −28.57% | −52.69% | −31.25% |
Return on Assets
ROIV
IMVT
FDMT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hrghxxtlm | Wkdy | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pftlnmtj | Fqbnxd | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rdnscmmy | Lzbkc | $97.8 Bil | |
MRNA
| Moderna Inc | Sgxfjfxd | Yhsb | $41.3 Bil | |
ARGX
| argenx SE ADR | Gyrgfxwv | Qhyzf | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Gwzpftchg | Vmsh | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fbjrjsdcj | Nlbjmrv | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jlsvlds | Vvpssw | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qcbbnrqw | Xlzbpj | $12.5 Bil | |
INCY
| Incyte Corp | Wbhtxxj | Gcnhcc | $11.6 Bil |